Proton-Coupled Organic Cation Antiporter-Mediated Uptake of Apomorphine Enantiomers in Human Brain Capillary Endothelial Cell Line hCMEC/D3
R(−)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson’s disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(−)-apomorphine and its S-enantiome...
Saved in:
Published in | Biological & pharmaceutical bulletin Vol. 37; no. 2; pp. 286 - 291 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Japan
The Pharmaceutical Society of Japan
01.02.2014
Pharmaceutical Society of Japan Japan Science and Technology Agency |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | R(−)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson’s disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(−)-apomorphine and its S-enantiomer in human brain, using human endothelial cell line hCMEC/D3 as a model. Uptake of R(−)- or S(+)-apomorphine into hCMEC/D3 cells was measured under various conditions to evaluate its time-, concentration-, energy- and ion-dependency. Inhibition by selected organic cations was also examined. Uptakes of both R(−)- and S(+)-apomorphine increased with time. The initial uptake velocities of R(−)- and S(+)-apomorphine were concentration-dependent, with similar Km and Vmax values. The cell-to-medium (C/M) ratio of R(−)-apomorphine was significantly reduced by pretreatment with sodium azide, but was not affected by replacement of extracellular sodium ion with N-methylglucamine or potassium. Intracellular alkalization markedly reduced the uptake, while intracellular acidification increased it, suggesting that the uptake is driven by an oppositely directed proton gradient. The C/M ratio was significantly decreased by amantadine, verapamil, pyrilamine and diphenhydramine (substrates or inhibitors of proton-coupled organic cation antiporter), while tetraethylammonium (substrate of organic cation transporters (OCTs)) and carnitine (substrate of carnitine/organic cation transporter 2; (OCTN2)) had no effect. R(−)-Apomorphine uptake was competitively inhibited by diphenhydramine. Our results indicate that R(−)-apomorphine transport in human blood–brain barrier (BBB) model cells is similar to S(+)-apomorphine uptake. The transport was dependent on an oppositely directed proton gradient, but was sodium- or membrane potential-independent. The transport characteristics were consistent with involvement of the previously reported proton-coupled organic cation antiporter. |
---|---|
AbstractList | R(-)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson's disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(-)-apomorphine and its S-enantiomer in human brain, using human endothelial cell line hCMEC/D3 as a model. Uptake of R(-)- or S(+)-apomorphine into hCMEC/D3 cells was measured under various conditions to evaluate its time-, concentration-, energy- and ion-dependency. Inhibition by selected organic cations was also examined. Uptakes of both R(-)- and S(+)-apomorphine increased with time. The initial uptake velocities of R(-)- and S(+)-apomorphine were concentration-dependent, with similar Km and Vmax values. The cell-to-medium (C/M) ratio of R(-)-apomorphine was significantly reduced by pretreatment with sodium azide, but was not affected by replacement of extracellular sodium ion with N-methylglucamine or potassium. Intracellular alkalization markedly reduced the uptake, while intracellular acidification increased it, suggesting that the uptake is driven by an oppositely directed proton gradient. The C/M ratio was significantly decreased by amantadine, verapamil, pyrilamine and diphenhydramine (substrates or inhibitors of proton-coupled organic cation antiporter), while tetraethylammonium (substrate of organic cation transporters (OCTs)) and carnitine (substrate of carnitine/organic cation transporter 2; (OCTN2)) had no effect. R(-)-Apomorphine uptake was competitively inhibited by diphenhydramine. Our results indicate that R(-)-apomorphine transport in human blood-brain barrier (BBB) model cells is similar to S(+)-apomorphine uptake. The transport was dependent on an oppositely directed proton gradient, but was sodium- or membrane potential-independent. The transport characteristics were consistent with involvement of the previously reported proton-coupled organic cation antiporter. R(-)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson's disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(-)-apomorphine and its S-enantiomer in human brain, using human endothelial cell line hCMEC/D3 as a model. Uptake of R(-)- or S(+)-apomorphine into hCMEC/D3 cells was measured under various conditions to evaluate its time-, concentration-, energy- and ion-dependency. Inhibition by selected organic cations was also examined. Uptakes of both R(-)- and S(+)-apomorphine increased with time. The initial uptake velocities of R(-)- and S(+)-apomorphine were concentration-dependent, with similar Km and Vmax values. The cell-to-medium (C/M) ratio of R(-)-apomorphine was significantly reduced by pretreatment with sodium azide, but was not affected by replacement of extracellular sodium ion with N-methylglucamine or potassium. Intracellular alkalization markedly reduced the uptake, while intracellular acidification increased it, suggesting that the uptake is driven by an oppositely directed proton gradient. The C/M ratio was significantly decreased by amantadine, verapamil, pyrilamine and diphenhydramine (substrates or inhibitors of proton-coupled organic cation antiporter), while tetraethylammonium (substrate of organic cation transporters (OCTs)) and carnitine (substrate of carnitine/organic cation transporter 2; (OCTN2)) had no effect. R(-)-Apomorphine uptake was competitively inhibited by diphenhydramine. Our results indicate that R(-)-apomorphine transport in human blood-brain barrier (BBB) model cells is similar to S(+)-apomorphine uptake. The transport was dependent on an oppositely directed proton gradient, but was sodium- or membrane potential-independent. The transport characteristics were consistent with involvement of the previously reported proton-coupled organic cation antiporter.R(-)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson's disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(-)-apomorphine and its S-enantiomer in human brain, using human endothelial cell line hCMEC/D3 as a model. Uptake of R(-)- or S(+)-apomorphine into hCMEC/D3 cells was measured under various conditions to evaluate its time-, concentration-, energy- and ion-dependency. Inhibition by selected organic cations was also examined. Uptakes of both R(-)- and S(+)-apomorphine increased with time. The initial uptake velocities of R(-)- and S(+)-apomorphine were concentration-dependent, with similar Km and Vmax values. The cell-to-medium (C/M) ratio of R(-)-apomorphine was significantly reduced by pretreatment with sodium azide, but was not affected by replacement of extracellular sodium ion with N-methylglucamine or potassium. Intracellular alkalization markedly reduced the uptake, while intracellular acidification increased it, suggesting that the uptake is driven by an oppositely directed proton gradient. The C/M ratio was significantly decreased by amantadine, verapamil, pyrilamine and diphenhydramine (substrates or inhibitors of proton-coupled organic cation antiporter), while tetraethylammonium (substrate of organic cation transporters (OCTs)) and carnitine (substrate of carnitine/organic cation transporter 2; (OCTN2)) had no effect. R(-)-Apomorphine uptake was competitively inhibited by diphenhydramine. Our results indicate that R(-)-apomorphine transport in human blood-brain barrier (BBB) model cells is similar to S(+)-apomorphine uptake. The transport was dependent on an oppositely directed proton gradient, but was sodium- or membrane potential-independent. The transport characteristics were consistent with involvement of the previously reported proton-coupled organic cation antiporter. R(−)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson’s disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(−)-apomorphine and its S-enantiomer in human brain, using human endothelial cell line hCMEC/D3 as a model. Uptake of R(−)- or S(+)-apomorphine into hCMEC/D3 cells was measured under various conditions to evaluate its time-, concentration-, energy- and ion-dependency. Inhibition by selected organic cations was also examined. Uptakes of both R(−)- and S(+)-apomorphine increased with time. The initial uptake velocities of R(−)- and S(+)-apomorphine were concentration-dependent, with similar Km and Vmax values. The cell-to-medium (C/M) ratio of R(−)-apomorphine was significantly reduced by pretreatment with sodium azide, but was not affected by replacement of extracellular sodium ion with N-methylglucamine or potassium. Intracellular alkalization markedly reduced the uptake, while intracellular acidification increased it, suggesting that the uptake is driven by an oppositely directed proton gradient. The C/M ratio was significantly decreased by amantadine, verapamil, pyrilamine and diphenhydramine (substrates or inhibitors of proton-coupled organic cation antiporter), while tetraethylammonium (substrate of organic cation transporters (OCTs)) and carnitine (substrate of carnitine/organic cation transporter 2; (OCTN2)) had no effect. R(−)-Apomorphine uptake was competitively inhibited by diphenhydramine. Our results indicate that R(−)-apomorphine transport in human blood–brain barrier (BBB) model cells is similar to S(+)-apomorphine uptake. The transport was dependent on an oppositely directed proton gradient, but was sodium- or membrane potential-independent. The transport characteristics were consistent with involvement of the previously reported proton-coupled organic cation antiporter. |
Author | Okura, Takashi Higuchi, Kei Deguchi, Yoshiharu Kitamura, Atsushi |
Author_xml | – sequence: 1 fullname: Okura, Takashi organization: Laboratory of Drug Disposition & Pharmacokinetics, Faculty of Pharma-Sciences, Teikyo University – sequence: 2 fullname: Higuchi, Kei organization: Laboratory of Drug Disposition & Pharmacokinetics, Faculty of Pharma-Sciences, Teikyo University – sequence: 3 fullname: Kitamura, Atsushi organization: Laboratory of Drug Disposition & Pharmacokinetics, Faculty of Pharma-Sciences, Teikyo University – sequence: 4 fullname: Deguchi, Yoshiharu organization: Laboratory of Drug Disposition & Pharmacokinetics, Faculty of Pharma-Sciences, Teikyo University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24257040$$D View this record in MEDLINE/PubMed |
BookMark | eNp1krtuFDEUhi0URDaBkhZZoqGZxLe5lcuwJEgbhYLUlsf2ZL147MH2FHkGXhrPblikSDS-6HznnN_n9wU4c95pAN5jdIUJa677qb_qMS0Qqmv6CqwwZXVRElyegRVqcVNUuGzOwUWMe5QZROgbcE4YKWvE0Ar8_h588q7o_DxZreB9eBTOSNiJZLyDa5fM5EPSobjTyoiUkYcpiZ8a-gGuJz_6MO2M03DjRGb9qEOExsHbeRQOfg4inzsxGWtFeMqQ8mmnrREWdtpauF1Sd93dprv-Qt-C14OwUb973i_Bw9fNj-622N7ffOvW20LWrEqFGvqhElJVhJQKUzm0CAvV5iBtkMS9Ik1PsBZMI4WrUjat6kvc5JvQFWGSXoJPx7pT8L9mHRMfTZRZjnDaz5Fj1rYYt02JMvrxBbr3c3BZ3UKxitUVWagPz9Tcj1rxKZgxP5f_HXMGiiMgg48x6OGEYMQXG3m2kWcb-cHGzNMXvDTp4EjKE7X_zbo5ZmUNRgrrnc3j_adYxro33npOEGY5h-bfwBGuOCLNsrSYENzW9aK3O1baxyQe9UmtCMlIqw99ac3Jspz6n6JyJwLXjv4BBevPiQ |
CitedBy_id | crossref_primary_10_4062_biomolther_2019_007 crossref_primary_10_1016_j_xphs_2017_05_007 crossref_primary_10_1080_17425247_2025_2462767 crossref_primary_10_1016_j_pharmthera_2022_108283 crossref_primary_10_1002_jps_24691 crossref_primary_10_1021_mp500516j crossref_primary_10_1124_dmd_123_001354 crossref_primary_10_3390_pharmaceutics14081683 crossref_primary_10_47493_abantmedj_1584839 crossref_primary_10_1002_bdd_2014 crossref_primary_10_1242_dmm_049410 crossref_primary_10_1016_j_xphs_2017_04_032 crossref_primary_10_1016_j_xphs_2016_10_006 crossref_primary_10_1007_s11064_016_2030_x crossref_primary_10_1248_bpb_b24_00329 crossref_primary_10_1007_s11095_022_03223_z crossref_primary_10_1124_dmd_115_068932 crossref_primary_10_1248_yakushi_14_00234_2 crossref_primary_10_1021_jm500786c crossref_primary_10_3390_molecules26185629 crossref_primary_10_1016_j_neuint_2014_04_015 crossref_primary_10_1016_j_jconrel_2017_03_034 crossref_primary_10_1016_j_xphs_2020_09_001 |
Cites_doi | 10.1002/syn.890150403 10.2133/dmpk.DMPK-13-RG-058 10.1152/ajpgi.2000.278.4.G563 10.1186/2045-8118-10-8 |
ContentType | Journal Article |
Copyright | 2014 The Pharmaceutical Society of Japan Copyright Japan Science and Technology Agency 2014 |
Copyright_xml | – notice: 2014 The Pharmaceutical Society of Japan – notice: Copyright Japan Science and Technology Agency 2014 |
CorporateAuthor | Teikyo University Faculty of Pharma-Sciences Laboratory of Drug Disposition & Pharmacokinetics |
CorporateAuthor_xml | – name: Laboratory of Drug Disposition & Pharmacokinetics – name: Faculty of Pharma-Sciences – name: Teikyo University |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7QR 7TK 7U9 8FD FR3 H94 P64 7X8 |
DOI | 10.1248/bpb.b13-00773 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database AIDS and Cancer Research Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Virology and AIDS Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1347-5215 |
EndPage | 291 |
ExternalDocumentID | 3206545581 24257040 10_1248_bpb_b13_00773 cs7biolo_2014_003702_016_0286_02912219770 article_bpb_37_2_37_b13_00773_article_char_en |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 23N 2WC 53G 5GY 6J9 ACGFO ACIWK ACPRK ADBBV AENEX AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BKOMP CS3 DIK DU5 E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH KQ8 MOJWN OK1 P2P RJT RZJ TR2 XSB ABJNI .55 1CY AAYXX AI. CITATION TKC VH1 X7M ZXP ZY4 ABTAH CGR CUY CVF ECM EIF NPM 7QP 7QR 7TK 7U9 8FD FR3 H94 P64 7X8 |
ID | FETCH-LOGICAL-c746t-dfbf6acd6225d13cf901ad9c74380c1bd28b21ea4e0d165c89db518e0dae624c3 |
ISSN | 0918-6158 1347-5215 |
IngestDate | Fri Jul 11 02:19:36 EDT 2025 Mon Jun 30 10:06:21 EDT 2025 Thu May 23 23:51:55 EDT 2024 Tue Jul 01 02:43:49 EDT 2025 Thu Apr 24 23:02:55 EDT 2025 Thu Jul 10 16:12:41 EDT 2025 Thu Aug 17 20:29:54 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c746t-dfbf6acd6225d13cf901ad9c74380c1bd28b21ea4e0d165c89db518e0dae624c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/bpb/37/2/37_b13-00773/_article/-char/en |
PMID | 24257040 |
PQID | 1494647620 |
PQPubID | 1966364 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_1499119850 proquest_journals_1494647620 pubmed_primary_24257040 crossref_primary_10_1248_bpb_b13_00773 crossref_citationtrail_10_1248_bpb_b13_00773 medicalonline_journals_cs7biolo_2014_003702_016_0286_02912219770 jstage_primary_article_bpb_37_2_37_b13_00773_article_char_en |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-02-01 |
PublicationDateYYYYMMDD | 2014-02-01 |
PublicationDate_xml | – month: 02 year: 2014 text: 2014-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan – name: Tokyo |
PublicationTitle | Biological & pharmaceutical bulletin |
PublicationTitleAlternate | Biol Pharm Bull |
PublicationYear | 2014 |
Publisher | The Pharmaceutical Society of Japan Pharmaceutical Society of Japan Japan Science and Technology Agency |
Publisher_xml | – name: The Pharmaceutical Society of Japan – name: Pharmaceutical Society of Japan – name: Japan Science and Technology Agency |
References | 5) Boström E, Simonsson US, Hammarlund-Udenaes M. In vivo blood–brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab. Dispos., 34, 1624–1631 (2006). 9) Kuwayama K, Inoue H, Kanamori T, Tsujikawa K, Miyaguchi H, Iwata Y, Miyauchi S, Kamo N, Kishi T. Uptake of 3,4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells. Biochim. Biophys. Acta, 1778, 42–50 (2008). 2) Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J., 19, 1872–1874 (2005). 13) Okura T, Ito R, Ishiguro N, Tamai I, Deguchi Y. Blood–brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci., 80, 1564–1571 (2007). 15) Cisternino S, Chapy H, André P, Smirnova M, Debray M, Scherrmann JM. Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood–brain barrier. AAPS J., 15, 299–307 (2013). 16) Tega Y, Akanuma S, Kubo Y, Terasaki T, Hosoya K. Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: involvement of a pyrilamine-sensitive organic cation transport process. Neurochem. Int., 62, 173–181 (2013). 3) Weksler B, Romero IA, Couraud PO. The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids and Barriers of the CNS, 10, 16 (2013). 10) André P, Debray M, Scherrmann JM, Cisternino S. Clonidine transport at the mouse blood–brain barrier by a new H+ antiporter that interacts with addictive drugs. J. Cereb. Blood Flow Metab., 29, 1293–1304 (2009). 12) Szabo Z, Ravert HT, Gözükara I, Geckle W, Seki C, Sostre S, Peller P, Monsein L, Natarajan TK, Links JM, Wong DF, Dannals RF, Wagner HN Jr. Noncompartmental and compartmental modeling of the kinetics of carbon-11 labeled pyrilamine in the human brain. Synapse, 15, 263–275 (1993). 1) Sam E, Sarre S, Michotte Y, Verbeke N. Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid. Eur. J. Pharmacol., 329, 9–15 (1997). 17) Armstrong J, Barlow RB. The ionization of phenolic amines, including apomorphine, dopamine and catecholamines and an assessment of zwitterion constants. Br. J. Pharmacol., 57, 501–516 (1976). 8) Okura T, Kato S, Deguchi Y. Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model. Drug Metab. Pharmacokinet., 2013, in press. 4) Shimomura K, Okura T, Kato S, Couraud PO, Schermann JM, Terasaki T, Deguchi Y. Functional expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model. Fluids and Barriers of the CNS, 10, 8 (2013). 11) Kubo Y, Shimizu Y, Kusagawa Y, Akanuma S, Hosoya K. Propranolol transport across the inner blood–retinal barrier: potential involvement of a novel organic cation transporter. J. Pharm. Sci., 102, 3332–3342 (2013). 6) Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood–brain barrier transport of oxycodone. Drug Metab. Dispos., 36, 2005–2013 (2008). 14) Mizuuchi H, Katsura T, Ashida K, Hashimoto Y, Inui KI. Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells. Am. J. Physiol. Gastrointest. Liver Physiol., 278, G563–G569 (2000). 7) Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, Jansson B, Björkman S, Terasaki T, Hammarlund-Udenaes M. Diphenhydramine active uptake at the blood–brain barrier and its interaction with oxycodone in vitro and in vivo. J. Pharm. Sci., 100, 3912–3923 (2011). 11 12 13 14 15 16 17 1 2 3 4 5 6 7 8 9 10 |
References_xml | – reference: 7) Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, Jansson B, Björkman S, Terasaki T, Hammarlund-Udenaes M. Diphenhydramine active uptake at the blood–brain barrier and its interaction with oxycodone in vitro and in vivo. J. Pharm. Sci., 100, 3912–3923 (2011). – reference: 6) Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood–brain barrier transport of oxycodone. Drug Metab. Dispos., 36, 2005–2013 (2008). – reference: 13) Okura T, Ito R, Ishiguro N, Tamai I, Deguchi Y. Blood–brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci., 80, 1564–1571 (2007). – reference: 17) Armstrong J, Barlow RB. The ionization of phenolic amines, including apomorphine, dopamine and catecholamines and an assessment of zwitterion constants. Br. J. Pharmacol., 57, 501–516 (1976). – reference: 2) Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J., 19, 1872–1874 (2005). – reference: 12) Szabo Z, Ravert HT, Gözükara I, Geckle W, Seki C, Sostre S, Peller P, Monsein L, Natarajan TK, Links JM, Wong DF, Dannals RF, Wagner HN Jr. Noncompartmental and compartmental modeling of the kinetics of carbon-11 labeled pyrilamine in the human brain. Synapse, 15, 263–275 (1993). – reference: 11) Kubo Y, Shimizu Y, Kusagawa Y, Akanuma S, Hosoya K. Propranolol transport across the inner blood–retinal barrier: potential involvement of a novel organic cation transporter. J. Pharm. Sci., 102, 3332–3342 (2013). – reference: 3) Weksler B, Romero IA, Couraud PO. The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids and Barriers of the CNS, 10, 16 (2013). – reference: 16) Tega Y, Akanuma S, Kubo Y, Terasaki T, Hosoya K. Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: involvement of a pyrilamine-sensitive organic cation transport process. Neurochem. Int., 62, 173–181 (2013). – reference: 1) Sam E, Sarre S, Michotte Y, Verbeke N. Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid. Eur. J. Pharmacol., 329, 9–15 (1997). – reference: 9) Kuwayama K, Inoue H, Kanamori T, Tsujikawa K, Miyaguchi H, Iwata Y, Miyauchi S, Kamo N, Kishi T. Uptake of 3,4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells. Biochim. Biophys. Acta, 1778, 42–50 (2008). – reference: 4) Shimomura K, Okura T, Kato S, Couraud PO, Schermann JM, Terasaki T, Deguchi Y. Functional expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model. Fluids and Barriers of the CNS, 10, 8 (2013). – reference: 15) Cisternino S, Chapy H, André P, Smirnova M, Debray M, Scherrmann JM. Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood–brain barrier. AAPS J., 15, 299–307 (2013). – reference: 5) Boström E, Simonsson US, Hammarlund-Udenaes M. In vivo blood–brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab. Dispos., 34, 1624–1631 (2006). – reference: 10) André P, Debray M, Scherrmann JM, Cisternino S. Clonidine transport at the mouse blood–brain barrier by a new H+ antiporter that interacts with addictive drugs. J. Cereb. Blood Flow Metab., 29, 1293–1304 (2009). – reference: 8) Okura T, Kato S, Deguchi Y. Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model. Drug Metab. Pharmacokinet., 2013, in press. – reference: 14) Mizuuchi H, Katsura T, Ashida K, Hashimoto Y, Inui KI. Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells. Am. J. Physiol. Gastrointest. Liver Physiol., 278, G563–G569 (2000). – ident: 2 – ident: 12 doi: 10.1002/syn.890150403 – ident: 17 – ident: 3 – ident: 5 – ident: 8 doi: 10.2133/dmpk.DMPK-13-RG-058 – ident: 1 – ident: 11 – ident: 10 – ident: 13 – ident: 14 doi: 10.1152/ajpgi.2000.278.4.G563 – ident: 16 – ident: 4 doi: 10.1186/2045-8118-10-8 – ident: 15 – ident: 6 – ident: 9 – ident: 7 |
SSID | ssj0007023 ssib058492369 ssib023156946 ssib002483627 ssib002822050 ssib017383521 |
Score | 2.1907063 |
Snippet | R(−)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson’s disease... R(-)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson's disease... |
SourceID | proquest pubmed crossref medicalonline jstage |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 286 |
SubjectTerms | Antiporters - metabolism apomorphine Apomorphine - pharmacokinetics Biological Transport Blood-Brain Barrier - metabolism blood–brain barrier Cations - metabolism Cell Line Dopamine Agonists - pharmacokinetics Endothelial Cells - metabolism hCMEC/D3 cell Humans Hydrogen-Ion Concentration Membrane Potentials Organic Cation Transport Proteins - metabolism proton-coupled organic cation antiporter Protons Sodium - metabolism Stereoisomerism |
Title | Proton-Coupled Organic Cation Antiporter-Mediated Uptake of Apomorphine Enantiomers in Human Brain Capillary Endothelial Cell Line hCMEC/D3 |
URI | https://www.jstage.jst.go.jp/article/bpb/37/2/37_b13-00773/_article/-char/en http://mol.medicalonline.jp/library/journal/download?GoodsID=cs7biolo/2014/003702/016&name=0286-0291e https://www.ncbi.nlm.nih.gov/pubmed/24257040 https://www.proquest.com/docview/1494647620 https://www.proquest.com/docview/1499119850 |
Volume | 37 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Biological and Pharmaceutical Bulletin, 2014/02/01, Vol.37(2), pp.286-291 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfGQAIJIdj4KAxkJLQXli4fzkclHijd0DQY4qGTxlNkx45WuiZVmzyUf4F_mEfu7CRNxiYxeLHa-JzEufs5dxffHSFvhCN5pKS0eMS4xVJPWCLiuBjayncAfYHeTXjyJTg6Zcdn_tnGxq_WrqWyEP3kx5VxJf_CVTgGfMUo2RtwtjkpHIDfwF9ogcPQ_hWPvy5yrAA8ysv5BSiOJq4ywag-ZOowKyY6bfnCOtEFOYDkdF7wqTLqZz7L4SGjlnmIu2EwDn-hd8cax_4HLB4B55pjXaLFCogkRmtdoIt9hB6_zzj0fHRyOIIZHHidz8OTZk3V0QjnHcd5J-U3Oninpa529HbMp1jbqeUOx1ItJnyoOfppUvBZNWBYLMvWgAPVDPiWw3G4bNl2azis3gldCSKC5NLN1dtY4REdgyKRtX2ZTgQ2sMkB31dmJfdYCFa2iRWtl3qTX6YSabe9btf5uM0_U0Dsj7eLyzBiQsxFX2BNDDs0VVguJeyuxCEGutgLYxcboI81fVz3YlAdyPAtctsFA8fVr5S14RbaujBhM7EqOyzcwH7n8h1t6s53MCgwU8T9mfnIZ5KtXG87aR1q_JA8qIwfOjQ394hsqGyLbA8zXuSzFd2lejuy_s6zRe6O6lKEW2S34tFqj47X8YLLPT2kSb2-2iY_u4igFSKoQQS9AhHUIILmKW0hgrYQQScZ1YigGhG0QQRtIYIiIigigmpE7B94j8npx8Px6Miqyo1YSciCwpKpSAOeyABecdLxkhRUZS4H0OlFduII6UbCdRRnypZO4CfRQArfieAfV4HLEu8J2czyTD0jlEkpRZgqN_UThkaYTLijXC_kEvQ_P-yRvZptcVLl4seSMBcx2uTAZS08jdD0yG5DPjdJaK4jfGdkoCG7kTD2yPuO5MTVWreMk2Wok8LFCFXMJwwCGuPmUDBPsBk4Lqg-YWj3yE4tbOvRDhuwgMHCD92vm26QIfw4yTOVl5oG9K5B5APNUyOkzSS0WwS0jef_N70X5N56pdkhm8WiVC_BpCjEK42-399nKmQ |
linkProvider | ABC ChemistRy |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Proton-Coupled+Organic+Cation+Antiporter-Mediated+Uptake+of+Apomorphine+Enantiomers+in+Human+Brain+Capillary+Endothelial+Cell+Line+hCMEC%2FD3&rft.jtitle=Biological+and+Pharmaceutical+Bulletin&rft.au=Okura%2C+Takashi&rft.au=Higuchi%2C+Kei&rft.au=Kitamura%2C+Atsushi&rft.au=Deguchi%2C+Yoshiharu&rft.date=2014-02-01&rft.pub=The+Pharmaceutical+Society+of+Japan&rft.issn=0918-6158&rft.eissn=1347-5215&rft.volume=37&rft.issue=2&rft.spage=286&rft.epage=291&rft_id=info:doi/10.1248%2Fbpb.b13-00773&rft.externalDocID=article_bpb_37_2_37_b13_00773_article_char_en |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-6158&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-6158&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-6158&client=summon |